SEC For	m 4																	
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STAT			-			ES IN B a) of the Sec			-	-	HIP	Estim	Numbe ated av	erage burde	3235-0287 n 0.5
									Investment									
1. Name and Address of Reporting Person* <u>Horn Patrick Taylor</u>				2. Issuer Name and Ticker or Trading Symbol <u>Fulcrum Therapeutics, Inc.</u> [FULC]									eck all applica Director	able)	ting Person(s) to Issuer 10% Own		wner	
(Last)	(Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 03/18/2024								2	X Officer (give title Other (specify below) below) Chief Medical Officer				specify
26 LANDSDOWNE STREET				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) CAMBRIDGE MA 02139													X Form filed by One Reporting Person Form filed by More than One Reporting Person				I	
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication														
		T		Devis		the a	affirmative o	defens	se conditions o	of Ru	le 10b5-1(c	c). See Instru	uction 10.		or written p	lan that	is intended	to satisfy
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date (Month/I				action	ction 2A. Deemed Execution Date,			, 3. 4. Se Transaction Code (Instr.		4. Securi	urities Acquired (A) or sed Of (D) (Instr. 3, 4 a		5. Amoun Securities Beneficia Owned Fo	s Form Ily (D) o bllowing (I) (In		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code \	v	Amount	(A) o (D)	r Price	Price Reported Transaction (Instr. 3 and				(Instr. 4)
			Table II -	Deriva (e.g., p	tive uts,	Sec call	urities Is, warr	Acq ants	uired, Dis s, options	spo s, co	osed of, onverti	, or Ben ble secu	eficially urities)	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode N	V (A)		(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (right to buy)	\$10.12	03/18/2024		1	A		400,000		(1)	03	3/17/2034	Common Stock	400,000	\$0.00	400,0	00	D	

Explanation of Responses:

1. This option was granted on March 18, 2024 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of March 18, 2024. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

/s/ Greg	g Tourangeau as
attorney	v-in-fact for Patrick
Horn	

** Signature of Reporting Person Date

03/20/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.